共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
3.
Andrés Norambuena Claudia Metz Lucas Vicu?a Antonia Silva Evelyn Pardo Claudia Oyanadel Loreto Massardo Alfonso González Andrea Soza 《The Journal of biological chemistry》2009,284(19):12670-12679
Galectins have been implicated in T cell homeostasis playing complementary
pro-apoptotic roles. Here we show that galectin-8 (Gal-8) is a potent
pro-apoptotic agent in Jurkat T cells inducing a complex phospholipase
D/phosphatidic acid signaling pathway that has not been reported for any
galectin before. Gal-8 increases phosphatidic signaling, which enhances the
activity of both ERK1/2 and type 4 phosphodiesterases (PDE4), with a
subsequent decrease in basal protein kinase A activity. Strikingly, rolipram
inhibition of PDE4 decreases ERK1/2 activity. Thus Gal-8-induced PDE4
activation releases a negative influence of cAMP/protein kinase A on ERK1/2.
The resulting strong ERK1/2 activation leads to expression of the death factor
Fas ligand and caspase-mediated apoptosis. Several conditions that decrease
ERK1/2 activity also decrease apoptosis, such as anti-Fas ligand blocking
antibodies. In addition, experiments with freshly isolated human peripheral
blood mononuclear cells, previously stimulated with anti-CD3 and anti-CD28,
show that Gal-8 is pro-apoptotic on activated T cells, most likely on a
subpopulation of them. Anti-Gal-8 autoantibodies from patients with systemic
lupus erythematosus block the apoptotic effect of Gal-8. These results
implicate Gal-8 as a novel T cell suppressive factor, which can be
counterbalanced by function-blocking autoantibodies in autoimmunity.Glycan-binding proteins of the galectin family have been increasingly
studied as regulators of the immune response and potential therapeutic agents
for autoimmune disorders (1).
To date, 15 galectins have been identified and classified according with the
structural organization of their distinctive monomeric or dimeric carbohydrate
recognition domain for β-galactosides
(2,
3). Galectins are secreted by
unconventional mechanisms and once outside the cells bind to and cross-link
multiple glycoconjugates both at the cell surface and at the extracellular
matrix, modulating processes as diverse as cell adhesion, migration,
proliferation, differentiation, and apoptosis
(4–10).
Several galectins have been involved in T cell homeostasis because of their
capability to kill thymocytes, activated T cells, and T cell lines
(11–16).
Pro-apoptotic galectins might contribute to shape the T cell repertoire in the
thymus by negative selection, restrict the immune response by eliminating
activated T cells at the periphery
(1), and help cancer cells to
escape the immune system by eliminating cancer-infiltrating T cells
(17). They have also a
promising therapeutic potential to eliminate abnormally activated T cells and
inflammatory cells (1). Studies
on the mostly explored galectins, Gal-1, -3, and -9
(14,
15,
18–20),
as well as in Gal-2 (13),
suggest immunosuppressive complementary roles inducing different pathways to
apoptosis. Galectin-8
(Gal-8)4 is one of the
most widely expressed galectins in human tissues
(21,
22) and cancerous cells
(23,
24). Depending on the cell
context and mode of presentation, either as soluble stimulus or extracellular
matrix, Gal-8 can promote cell adhesion, spreading, growth, and apoptosis
(6,
7,
9,
10,
22,
25). Its role has been mostly
studied in relation to tumor malignancy
(23,
24). However, there is some
evidence regarding a role for Gal-8 in T cell homeostasis and autoimmune or
inflammatory disorders. For instance, the intrathymic expression and
pro-apoptotic effect of Gal-8 upon CD4highCD8high
thymocytes suggest a role for Gal-8 in shaping the T cell repertoire
(16). Gal-8 could also
modulate the inflammatory function of neutrophils
(26), Moreover Gal-8-blocking
agents have been detected in chronic autoimmune disorders
(10,
27,
28). In rheumatoid arthritis,
Gal-8 has an anti-inflammatory action, promoting apoptosis of synovial fluid
cells, but can be counteracted by a specific rheumatoid version of CD44
(CD44vRA) (27). In systemic
lupus erythematosus (SLE), a prototypic autoimmune disease, we recently
described function-blocking autoantibodies against Gal-8
(10,
28). Thus it is important to
define the role of Gal-8 and the influence of anti-Gal-8 autoantibodies in
immune cells.In Jurkat T cells, we previously reported that Gal-8 interacts with
specific integrins, such as α1β1, α3β1, and
α5β1 but not α4β1, and as a matrix protein promotes cell
adhesion and asymmetric spreading through activation of the extracellular
signal-regulated kinases 1 and 2 (ERK1/2)
(10). These early effects
occur within 5–30 min. However, ERK1/2 signaling supports long term
processes such as T cell survival or death, depending on the moment of the
immune response. During T cell activation, ERK1/2 contributes to enhance the
expression of interleukin-2 (IL-2) required for T cell clonal expansion
(29). It also supports T cell
survival against pro-apoptotic Fas ligand (FasL) produced by themselves and by
other previously activated T cells
(30,
31). Later on, ERK1/2 is
required for activation-induced cell death, which controls the extension of
the immune response by eliminating recently activated and restimulated T cells
(32,
33). In activation-induced
cell death, ERK1/2 signaling contributes to enhance the expression of FasL and
its receptor Fas/CD95 (32,
33), which constitute a
preponderant pro-apoptotic system in T cells
(34). Here, we ask whether
Gal-8 is able to modulate the intensity of ERK1/2 signaling enough to
participate in long term processes involved in T cell homeostasis.The functional integration of ERK1/2 and PKA signaling
(35) deserves special
attention. cAMP/PKA signaling plays an immunosuppressive role in T cells
(36) and is altered in SLE
(37). Phosphodiesterases
(PDEs) that degrade cAMP release the immunosuppressive action of cAMP/PKA
during T cell activation (38,
39). PKA has been described to
control the activity of ERK1/2 either positively or negatively in different
cells and processes (35). A
little explored integration among ERK1/2 and PKA occurs via phosphatidic acid
(PA) and PDE signaling. Several stimuli activate phospholipase D (PLD) that
hydrolyzes phosphatidylcholine into PA and choline. Such PLD-generated PA
plays roles in signaling interacting with a variety of targeting proteins that
bear PA-binding domains (40).
In this way PA recruits Raf-1 to the plasma membrane
(41). It is also converted by
phosphatidic acid phosphohydrolase (PAP) activity into diacylglycerol (DAG),
which among other functions, recruits and activates the GTPase Ras
(42). Both Ras and Raf-1 are
upstream elements of the ERK1/2 activation pathway
(43). In addition, PA binds to
and activates PDEs of the type 4 subfamily (PDE4s) leading to decreased cAMP
levels and PKA down-regulation
(44). The regulation and role
of PA-mediated control of ERK1/2 and PKA remain relatively unknown in T cell
homeostasis, because it is also unknown whether galectins stimulate the PLD/PA
pathway.Here we found that Gal-8 induces apoptosis in Jurkat T cells by triggering
cross-talk between PKA and ERK1/2 pathways mediated by PLD-generated PA. Our
results for the first time show that a galectin increases the PA levels,
down-regulates the cAMP/PKA system by enhancing rolipram-sensitive PDE
activity, and induces an ERK1/2-dependent expression of the pro-apoptotic
factor FasL. The enhanced PDE activity induced by Gal-8 is required for the
activation of ERK1/2 that finally leads to apoptosis. Gal-8 also induces
apoptosis in human peripheral blood mononuclear cells (PBMC), especially after
activating T cells with anti-CD3/CD28. Therefore, Gal-8 shares with other
galectins the property of killing activated T cells contributing to the T cell
homeostasis. The pathway involves a particularly integrated signaling context,
engaging PLD/PA, cAMP/PKA, and ERK1/2, which so far has not been reported for
galectins. The pro-apoptotic function of Gal-8 also seems to be unique in its
susceptibility to inhibition by anti-Gal-8 autoantibodies. 相似文献
4.
Xiaojun Li C. T. Ranjith-Kumar Monica T. Brooks S. Dharmaiah Andrew B. Herr Cheng Kao Pingwei Li 《The Journal of biological chemistry》2009,284(20):13881-13891
The RIG-I-like receptors (RLRs), RIG-I and MDA5, recognize single-stranded
RNA with 5′ triphosphates and double-stranded RNA (dsRNA) to initiate
innate antiviral immune responses. LGP2, a homolog of RIG-I and MDA5 that
lacks signaling capability, regulates the signaling of the RLRs. To establish
the structural basis of dsRNA recognition by the RLRs, we have determined the
2.0-Å resolution crystal structure of human LGP2 C-terminal domain bound
to an 8-bp dsRNA. Two LGP2 C-terminal domain molecules bind to the termini of
dsRNA with minimal contacts between the protein molecules. Gel filtration
chromatography and analytical ultracentrifugation demonstrated that LGP2 binds
blunt-ended dsRNA of different lengths, forming complexes with 2:1
stoichiometry. dsRNA with protruding termini bind LGP2 and RIG-I weakly and do
not stimulate the activation of RIG-I efficiently in cells. Surprisingly,
full-length LGP2 containing mutations that abolish dsRNA binding retained the
ability to inhibit RIG-I signaling.The innate immune response is the first line of defense against invading
pathogens; it is the ubiquitous system of defense against microbial infections
(1). Toll-like receptors
(TLRs)3 and RIG-I
(retinoic acid-inducible gene
1)-like receptors (RLRs) play key roles in innate immune response
toward viral infection
(2-5).
Toll-like receptors TLR3, TLR7, and TLR8 sense viral RNA released in the
endosome following phagocytosis of the pathogens
(6). RIG-I-like receptors RIG-I
and MDA5 detect viral RNA from replicating viruses in infected cells
(3,
7,
8). Stimulation of these
receptors leads to the induction of type I interferons (IFNs) and other
proinflammatory cytokines, conferring antiviral activity to the host cells and
activating the acquired immune responses
(4,
9).RIG-I discriminates between viral and host RNA through specific recognition
of the uncapped 5′-triphosphate of single-stranded RNA (5′ ppp
ssRNA) generated by viral RNA polymerases
(10,
11). In addition, RIG-I also
recognizes double-stranded RNA generated during RNA virus replication
(7,
12). Transfection of cells
with synthetic double-stranded RNA stimulates the activation of RIG-I
(13,
14). Synthetic dsRNA mimics,
such as polyinosinic-polycytidylic acid (poly(I·C)), can activate MDA5
when introduced into the cytoplasm of cells. Digestion of poly(I·C)
with RNase III transforms poly(I·C) from a ligand for MDA5 into a
ligand for RIG-I, suggesting that MDA5 recognizes long dsRNA, whereas RIG-I
recognizes short dsRNA (15).
Studies of RIG-I and MDA5 knock-out mice confirmed the essential roles of
these receptors in antiviral immune responses and demonstrated that they sense
different sets of RNA viruses
(12,
16).RIG-I and MDA5 contain two caspase recruiting domains (CARDs) at their N
termini, a DEX(D/H) box RNA helicase domain, and a C-terminal
regulatory or repressor domain (CTD). The helicase domain and the CTD are
responsible for viral RNA binding, whereas the CARDs are required for
signaling (3,
8). The current model of RIG-I
activation suggests that under resting conditions RIG-I is in a suppressed
conformation, and viral RNA binding triggers a conformation change that leads
to the exposure of the CARDs for the recruitment of the downstream protein
IPS-1 (also known as MAVS, Cardif, or VISA)
(14,
17). Limited proteolysis of
the RIG-I·dsRNA complex showed that RIG-I residues 792-925 of the CTD
are involved in dsRNA and 5′ ppp ssRNA binding
(14). The CTD of RIG-I
overlaps with the C terminus of the previously identified repressor domain
(18). The structures of RIG-I
and LGP2 (laboratory of genetics and
physiology 2) CTD in isolation have been determined by
x-ray crystallography and NMR spectroscopy
(14,
19,
20). A large, positively
charged surface on RIG-I recognizes the 5′ triphosphate group of viral
ssRNA (14,
19). RNA binding studies by
titrating RIG-I CTD with dsRNA and 5′ ppp ssRNA suggested that
overlapping sets of residues on this charged surface are involved in RNA
binding (14). Mutagenesis of
several positively charged residues on this surface either reduces or disrupts
RNA binding by RIG-I, and these mutations also affect the induction of
IFN-β in vivo
(14,
19). However, the exact nature
of how the RLRs recognize viral RNA and how RNA binding activates these
receptors remains to be established.LGP2 is a homolog of RIG-I and MDA5 that lacks the CARDs and thus has no
signaling capability (21,
22). The expression of LGP2 is
inducible by dsRNA or IFN treatment as well as virus infection
(21). Overexpression of LGP2
inhibits Sendai virus and Newcastle disease virus signaling
(21). When coexpressed with
RIG-I, LGP2 can inhibit RIG-I signaling through the interaction of its CTD
with the CARD and the helicase domain of RIG-I
(18). LGP2 could suppress
RIG-I signaling by three possible ways
(23): 1) binding RNA with high
affinity, thereby sequestering RNA ligands from RIG-I; 2) interacting directly
with RIG-I to block the assembly of the signaling complex; and 3) competing
with IKKi (IκB kinase ε) in the NF-κB signaling pathway for a
common binding site on IPS-1. To elucidate the structural basis of dsRNA
recognition by the RLRs, we have crystallized human LGP2 CTD (residues
541-678) bound to an 8-bp double-stranded RNA and determined the structure of
the complex at 2.0 Å resolution. The structure revealed that LGP2 CTD
binds to the termini of dsRNA. Mutagenesis and functional studies showed that
dsRNA binding is likely not required for the inhibition of RIG-I signaling by
LGP2. 相似文献
5.
6.
7.
Michael S. Friedman Sivan M. Oyserman Kurt D. Hankenson 《The Journal of biological chemistry》2009,284(21):14117-14125
Wnt11 signals through both canonical (β-catenin) and non-canonical
pathways and is up-regulated during osteoblast differentiation and fracture
healing. In these studies, we evaluated the role of Wnt11 during
osteoblastogenesis. Wnt11 overexpression in MC3T3E1 pre-osteoblasts increases
β-catenin accumulation and promotes bone morphogenetic protein
(BMP)-induced expression of alkaline phosphatase and mineralization. Wnt11
dramatically increases expression of the osteoblast-associated genes
Dmp1 (dentin matrix protein 1), Phex (phosphate-regulating
endopeptidase homolog), and Bsp (bone sialoprotein). Wnt11 also
increases expression of Rspo2 (R-spondin 2), a secreted factor known
to enhance Wnt signaling. Overexpression of Rspo2 is sufficient for increasing
Dmp1, Phex, and Bsp expression and promotes bone
morphogenetic protein-induced mineralization. Knockdown of Rspo2 abrogates
Wnt11-mediated osteoblast maturation. Antagonism of T-cell factor
(Tcf)/β-catenin signaling with dominant negative Tcf blocks
Wnt11-mediated expression of Dmp1, Phex, and Rspo2
and decreases mineralization. However, dominant negative Tcf fails to block
the osteogenic effects of Rspo2 overexpression. These studies show that Wnt11
signals through β-catenin, activating Rspo2 expression, which is
then required for Wnt11-mediated osteoblast maturation.Wnt signaling is a key regulator of osteoblast differentiation and
maturation. In mesenchymal stem cell lines, canonical Wnt signaling by Wnt10b
enhances osteoblast differentiation
(1). Canonical Wnt signaling
through β-catenin has also been shown to enhance the chondroinductive and
osteoinductive properties of
BMP22
(2,
3). During BMP2-induced
osteoblast differentiation of mesenchymal stem cell lines, cross-talk between
BMP and Wnt pathways converges through the interaction of Smad4 with
β-catenin (2).Canonical Wnt signaling is also critical for skeletal development and
homeostasis. During limb development, expression of Wnt3a in the apical
ectodermal ridge of limb buds maintains cells in a highly proliferative and
undifferentiated state (4,
5). Disruption of canonical Wnt
signaling in Lrp5/Lrp6 compound knock-out mice results in limb- and
digit-patterning defects (6).
Wnt signaling is also involved in the maintenance of post-natal bone mass.
Gain of function in the Wnt co-receptor Lrp5 leads to increased bone mass,
whereas loss of Lrp5 function is associated with decreased bone mass and
osteoporosis pseudoglioma syndrome
(7,
8). Mice with increased Wnt10b
expression have increased trabecular bone, whereas Wnt10b-deficient mice have
reduced trabecular bone (9).
Similarly, mice nullizygous for the Wnt antagonist sFrp1 have increased
trabecular bone accrual throughout adulthood
(10).Although canonical Wnt signaling regulates osteoblastogenesis and bone
formation, the profile of endogenous Wnts that play a role in osteoblast
differentiation and maturation is not well described. During development,
Wnt11 is expressed in the perichondrium and in the axial skeleton and sternum
(11). Wnt11 expression is
increased during glucocorticoid-induced osteogenesis
(12), indicating a potential
role for Wnt11 in osteoblast differentiation. Interestingly, Wnt11 activates
both β-catenin-dependent as well as β-catenin-independent signaling
pathways (13). Targeted
disruption of Wnt11 results in late embryonic/early post-natal death because
of cardiac dysfunction (14).
Although these mice have no reported skeletal developmental abnormalities,
early lethality obfuscates a detailed examination of post-natal skeletal
modeling and remodeling.In murine development, Wnt11 expression overlaps with the expression of
R-spondin 2 (Rspo2) in the apical ectodermal ridge
(11,
15). R-spondins are a novel
family of proteins that share structural features, including two conserved
cysteinerich furin-like domains and a thrombospondin type I repeat
(16). The four R-spondin
family members can activate canonical Wnt signaling
(15,
17–19).
Rspo3 interacts with Frizzled 8 and Lrp6 and enhances Wnt ligand signaling.
Rspo1 enhances Wnt signaling by interacting with Lrp6 and inhibiting
Dkk-mediated receptor internalization
(20). Rspo1 was also shown to
potentiate Wnt3a-mediated osteoblast differentiation
(21). Rspo2 knock-out
mice, which die at birth, have limb patterning defects associated with altered
β-catenin signaling
(22–24).
However, the role of Rspo2 in osteoblast differentiation and maturation
remains unclear.Herein we report that Wnt11 overexpression in MC3T3E1 pre-osteoblasts
activates β-catenin and augments BMP-induced osteoblast maturation and
mineralization. Wnt11 increases the expression of Rspo2.
Overexpression of Rspo2 in MC3T3E1 is sufficient for augmenting BMP-induced
osteoblast maturation and mineralization. Although antagonism of
Tcf/β-catenin signaling blocks the osteogenic effects of Wnt11, Rspo2
rescues this block, and knockdown of Rspo2 shows that it is required for
Wnt11-mediated osteoblast maturation and mineralization. These studies
identify both Wnt11 and Rspo2 as novel mediators of osteoblast maturation and
mineralization. 相似文献
8.
Siying Wang Wen-Mei Yu Wanming Zhang Keith R. McCrae Benjamin G. Neel Cheng-Kui Qu 《The Journal of biological chemistry》2009,284(2):913-920
Mutations in SHP-2 phosphatase (PTPN11) that cause hyperactivation
of its catalytic activity have been identified in Noonan syndrome and various
childhood leukemias. Recent studies suggest that the gain-of-function (GOF)
mutations of SHP-2 play a causal role in the pathogenesis of these diseases.
However, the molecular mechanisms by which GOF mutations of SHP-2 induce these
phenotypes are not fully understood. Here, we show that GOF mutations in
SHP-2, such as E76K and D61G, drastically increase spreading and migration of
various cell types, including hematopoietic cells, endothelial cells, and
fibroblasts. More importantly, in vivo angiogenesis in SHP-2 D61G
knock-in mice is also enhanced. Mechanistic studies suggest that the increased
cell migration is attributed to the enhanced β1 integrin outside-in
signaling. In response to β1 integrin cross-linking or fibronectin
stimulation, activation of ERK and Akt kinases is greatly increased by SHP-2
GOF mutations. Also, integrin-induced activation of RhoA and Rac1 GTPases is
elevated. Interestingly, mutant cells with the SHP-2 GOF mutation (D61G) are
more sensitive than wild-type cells to the suppression of cell motility by
inhibition of these pathways. Collectively, these studies reaffirm the
positive role of SHP-2 phosphatase in cell motility and suggest a new
mechanism by which SHP-2 GOF mutations contribute to diseases.SHP-2, a multifunctional SH2 domain-containing protein-tyrosine phosphatase
implicated in diverse cell signaling processes
(1–3),
plays a critical role in cellular function. Homozygous deletion of Exon
2 (4) or Exon 3
(5) of the SHP-2 gene
(PTPN11) in mice leads to early embryonic lethality prior to and at
midgestation, respectively. SHP-2 null mutant mice die much earlier, at
peri-implantation (4). Exon
3 deletion mutation of SHP-2 blocks hematopoietic potential of embryonic
stem cells both in vitro and in vivo
(6–8),
whereas SHP-2 null mutation causes inner cell mass death and diminished
trophoblast stem cell survival
(4). Recent studies on SHP-2
conditional knock-out or tissue-specific knock-out mice have further revealed
an array of important functions of this phosphatase in various physiological
processes
(9–12).
The phenotypes demonstrated by loss of SHP-2 function are apparently
attributed to the role of SHP-2 in the cell signaling pathways induced by
growth factors/cytokines. SHP-2 generally promotes signal transmission in
growth factor/cytokine signaling in both catalytic-dependent and -independent
fashion
(1–3).
The positive role of SHP-2 in the intracellular signaling processes, in
particular, the ERK3
and PI3K/Akt kinase pathways, has been well established, although the
underlying mechanism remains elusive, in particular, the signaling function of
the catalytic activity of SHP-2 in these pathways is poorly understood.In addition to the role of SHP-2 in cell proliferation and differentiation,
the phenotypes induced by loss of SHP-2 function may be associated with its
role in cell migration. Indeed, dominant negative SHP-2 disrupts
Xenopus gastrulation, causing tail truncations
(13,
14). Targeted Exon 3
deletion mutation in SHP-2 results in decreased cell spreading, migration
(15,
16), and impaired limb
development in the chimeric mice
(7). The role of SHP-2 in cell
adhesion and migration has also been demonstrated by catalytically inactive
mutant SHP-2-overexpressing cells
(17–20).
The molecular mechanisms by which SHP-2 regulates these cellular processes,
however, have not been well defined. For example, the role of SHP-2 in the
activation of the Rho family small GTPases that is critical for cell motility
is still controversial. Both positive
(19,
21,
22) and negative roles
(18,
23) for SHP-2 in this context
have been reported. Part of the reason for this discrepancy might be due to
the difference in the cell models used. Catalytically inactive mutant SHP-2
was often used to determine the role of SHP-2 in cell signaling. In the
catalytically inactive mutant SHP-2-overexpressing cells, the catalytic
activity of endogenous SHP-2 is inhibited. However, as SHP-2 also functions
independent of its catalytic activity, overexpression of catalytically
deficient SHP-2 may also increase its scaffolding function, generating complex
effects.The critical role of SHP-2 in cellular function is further underscored by
the identification of SHP-2 mutations in human diseases. Genetic lesions in
PTPN11 that cause hyperactivation of SHP-2 catalytic activity have
been identified in the developmental disorder Noonan syndrome
(24) and various childhood
leukemias, including juvenile myelomonocytic leukemia (JMML), B cell acute
lymphoblastic leukemia, and acute myeloid leukemia
(25,
26). In addition, activating
mutations in SHP-2 have been identified in sporadic solid tumors
(27). The SHP-2 mutations
appear to play a causal role in the development of these diseases as SHP-2
mutations and other JMML-associated Ras or Neurofibromatosis 1 mutations are
mutually exclusive in the patients
(24–27).
Moreover, single SHP-2 gain-of-function (GOF) mutations are sufficient to
induce Noonan syndrome, cytokine hypersensitivity in hematopoietic progenitor
cells, and JMML-like myeloproliferative disease in mice
(28–32).
Gain-of-function cell models derived from the newly available SHP-2 GOF
mutation (D61G) knock-in mice
(28) now provide us with a
good opportunity to clarify the role of SHP-2 in cell motility. Unlike the
dominant negative approach in which overexpression of mutant forms of SHP-2
generates complex effects, the SHP-2 D61G knock-in model eliminates this
possibility as the mutant SHP-2 is expressed at the physiological level
(28). Additionally, defining
signaling functions of GOF mutant SHP-2 in cell movement can also help
elucidate the molecular mechanisms by which SHP-2 mutations contribute to the
relevant diseases. 相似文献
9.
Xiufeng Song Sergio Coffa Haian Fu Vsevolod V. Gurevich 《The Journal of biological chemistry》2009,284(1):685-695
Arrestins bind active phosphorylated G protein-coupled receptors,
precluding G protein activation and channeling signaling to alternative
pathways. Arrestins also function as mitogen-activated protein kinase (MAPK)
scaffolds, bringing together three components of MAPK signaling modules. Here
we have demonstrated that all four vertebrate arrestins interact with JNK3,
MKK4, and ASK1, but only arrestin3 facilitates JNK3 activation. Thus, the
functional specificity of arrestins is not determined by differential binding
of the kinases. Using receptor binding-impaired mutant, we have shown that
free arrestin3 readily promotes JNK3 phosphorylation. We identified key
arrestin-binding elements in JNK3 and ASK1 and investigated the molecular
interactions of arrestin2 and arrestin3 and their individual domains with the
components of the two MAPK cascades, ASK1-MKK4-JNK3 and c-Raf-1-MEK1-ERK2. We
found that both arrestin domains interact with all six kinases. These findings
shed new light on the mechanism of arrestin-mediated MAPK activation and the
spatial arrangement of the three kinases on arrestin molecule.Arrestins are multifunctional regulators of cell signaling
(1,
2). Arrestins, which bind
active phosphorylated G protein-coupled receptors
(GPCRs),2 which play a
major role in receptor desensitization and internalization
(3,
4). With the identification of
numerous non-receptor binding partners, the classical paradigm of arrestin
function has been expanded, implicating arrestins in mitogen-activated protein
kinase (MAPK) activation, protein ubiquitination, chemotaxis, apoptosis, and
other cellular functions (2,
5-11).The first indication that arrestins function as signaling adapters came
from the studies of arrestin-dependent c-Src recruitment to the receptors,
which results in the activation of extracellular signal-regulated kinases
(ERK1/2) (10,
12,
13). Subsequently, arrestin2
and arrestin3 in complex with different receptors were reported to scaffold
JNK3 (9), ERK1/2
(8,
14), and p38
(15,
16) activation cascades.
Although arrestins play an important role in regulating different MAPK
pathways, the mechanism of arrestin-dependent assembly of MAP kinases into a
signaling complex remains largely unexplored. Existing models have limited
predictive value. For example, the idea that JNK3 is activated solely by
arrestin3 because this arrestin subtype has unique ability to bind JNK3
(9,
17) was not supported by
further experimentation
(18-20).
Similarly, the hypothesis that only receptor-bound arrestins interact with MAP
kinases (8,
9) was not confirmed
(17-20).Here we addressed several key mechanistic issues in arrestin-dependent MAPK
signaling. First, we show that the scaffolding function is not limited to
receptor-bound arrestin; free arrestin3 facilitates ASK1-mediated JNK3
activation, indicating that arrestins are not exclusively receptor-regulated
adapters as thought previously. Second, we show that all four mammalian
arrestins bind each component of the JNK3 cascade with comparable affinity,
demonstrating that binding does not necessarily translate into activation.
This finding establishes the mechanistic basis of the
“dominant-negative” effect of certain arrestin subtypes. Third,
using truncated forms of ASK1 and JNK3, we identified the major
arrestin-binding elements of these two kinases. Finally, we show that every
kinase in JNK3 and ERK2 activation cascades binds both arrestin domains. Based
on these findings, we propose a functional model of arrestin-dependent
regulation of MAPK activity and a new structural model of the arrestin-MAPK
multiprotein signaling complex. 相似文献
10.
As obligate intracellular parasites, viruses exploit diverse cellular
signaling machineries, including the mitogen-activated protein-kinase pathway,
during their infections. We have demonstrated previously that the open reading
frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus interacts with p90
ribosomal S6 kinases (RSKs) and strongly stimulates their kinase activities
(Kuang, E., Tang, Q., Maul, G. G., and Zhu, F.
(2008) J. Virol. 82
,1838
-1850). Here, we define the
mechanism by which ORF45 activates RSKs. We demonstrated that binding of ORF45
to RSK increases the association of extracellular signal-regulated kinase
(ERK) with RSK, such that ORF45, RSK, and ERK formed high molecular mass
protein complexes. We further demonstrated that the complexes shielded active
pERK and pRSK from dephosphorylation. As a result, the complex-associated RSK
and ERK were activated and sustained at high levels. Finally, we provide
evidence that this mechanism contributes to the sustained activation of ERK
and RSK in Kaposi sarcoma-associated herpesvirus lytic replication.The extracellular signal-regulated kinase
(ERK)2
mitogen-activated protein kinase (MAPK) signaling pathway has been implicated
in diverse cellular physiological processes including proliferation, survival,
growth, differentiation, and motility
(1-4)
and is also exploited by a variety of viruses such as Kaposi
sarcoma-associated herpesvirus (KSHV), human cytomegalovirus, human
immunodeficiency virus, respiratory syncytial virus, hepatitis B virus,
coxsackie, vaccinia, coronavirus, and influenza virus
(5-17).
The MAPK kinases relay the extracellular signaling through sequential
phosphorylation to an array of cytoplasmic and nuclear substrates to elicit
specific responses (1,
2,
18). Phosphorylation of MAPK
is reversible. The kinetics of deactivation or duration of signaling dictates
diverse biological outcomes
(19,
20). For example, sustained
but not transient activation of ERK signaling induces the differentiation of
PC12 cells into sympathetic-like neurons and transformation of NIH3T3 cells
(20-22).
During viral infection, a unique biphasic ERK activation has been observed for
some viruses (an early transient activation triggered by viral binding or
entry and a late sustained activation correlated with viral gene expression),
but the responsible viral factors and underlying mechanism for the sustained
ERK activation remain largely unknown
(5,
8,
13,
23).The p90 ribosomal S6 kinases (RSKs) are a family of serine/threonine
kinases that lie at the terminus of the ERK pathway
(1,
24-26).
In mammals, four isoforms are known, RSK1 to RSK4. Each one has two
catalytically functional kinase domains, the N-terminal kinase domain (NTKD)
and C-terminal kinase domain (CTKD) as well as a linker region between the
two. The NTKD is responsible for phosphorylation of exogenous substrates, and
the CTKD and linker region regulate RSK activation
(1,
24,
25). In quiescent cells ERK
binds to the docking site in the C terminus of RSK
(27-29).
Upon mitogen stimulation, ERK is activated by its upstream MAPK/ERK kinase
(MEK). The active ERK phosphorylates Thr-359/Ser-363 of RSK in the linker
region (amino acid numbers refer to human RSK1) and Thr-573 in the CTKD
activation loop. The activated CTKD then phosphorylates Ser-380 in the linker
region, creating a docking site for 3-phosphoinositide-dependent protein
kinase-1. The 3-phosphoinositide-dependent protein kinase-1 phosphorylates
Ser-221 of RSK in the activation loop and activates the NTKD. The activated
NTKD autophosphorylates the serine residue near the ERK docking site, causing
a transient dissociation of active ERK from RSK
(25,
26,
28). The stimulation of
quiescent cells by a mitogen such as epidermal growth factor or a phorbol
ester such as 12-O-tetradecanoylphorbol-13-acetate (TPA) usually
results in a transient RSK activation that lasts less than 30 min. RSKs have
been implicated in regulating cell survival, growth, and proliferation.
Mutation or aberrant expression of RSK has been implicated in several human
diseases including Coffin-Lowry syndrome and prostate and breast cancers
(1,
24,
25,
30-32).KSHV is a human DNA tumor virus etiologically linked to Kaposi sarcoma,
primary effusion lymphoma, and a subset of multicentric Castleman disease
(33,
34). Infection and
reactivation of KSHV activate multiple MAPK pathways
(6,
12,
35). Noticeably, the ERK/RSK
activation is sustained late during KSHV primary infection and reactivation
from latency (5,
6,
12,
23), but the mechanism of the
sustained ERK/RSK activation is unclear. Recently, we demonstrated that ORF45,
an immediate early and also virion tegument protein of KSHV, interacts with
RSK1 and RSK2 and strongly stimulates their kinase activities
(23). We also demonstrated
that the activation of RSK plays an essential role in KSHV lytic replication
(23). In the present study we
determined the mechanism of ORF45-induced sustained ERK/RSK activation. We
found that ORF45 increases the association of RSK with ERK and protects them
from dephosphorylation, causing sustained activation of both ERK and RSK. 相似文献
11.
Kuen-Feng Chen Pei-Yen Yeh Chiun Hsu Chih-Hung Hsu Yen-Shen Lu Hsing-Pang Hsieh Pei-Jer Chen Ann-Lii Cheng 《The Journal of biological chemistry》2009,284(17):11121-11133
Hepatocellular carcinoma (HCC) is one of the most common and aggressive
human malignancies. Recombinant tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is a promising anti-tumor agent. However,
many HCC cells show resistance to TRAIL-induced apoptosis. In this study, we
showed that bortezomib, a proteasome inhibitor, overcame TRAIL resistance in
HCC cells, including Huh-7, Hep3B, and Sk-Hep1. The combination of bortezomib
and TRAIL restored the sensitivity of HCC cells to TRAIL-induced apoptosis.
Comparing the molecular change in HCC cells treated with these agents, we
found that down-regulation of phospho-Akt (P-Akt) played a key role in
mediating TRAIL sensitization of bortezomib. The first evidence was that
bortezomib down-regulated P-Akt in a dose- and time-dependent manner in
TRAIL-treated HCC cells. Second, , a PI3K inhibitor, also sensitized
resistant HCC cells to TRAIL-induced apoptosis. Third, knocking down Akt1 by
small interference RNA also enhanced TRAIL-induced apoptosis in Huh-7 cells.
Finally, ectopic expression of mutant Akt (constitutive active) in HCC cells
abolished TRAIL sensitization effect of bortezomib. Moreover, okadaic acid, a
protein phosphatase 2A (PP2A) inhibitor, reversed down-regulation of P-Akt in
bortezomib-treated cells, and PP2A knockdown by small interference RNA also
reduced apoptosis induced by the combination of TRAIL and bortezomib,
indicating that PP2A may be important in mediating the effect of bortezomib on
TRAIL sensitization. Together, bortezomib overcame TRAIL resistance at
clinically achievable concentrations in hepatocellular carcinoma cells, and
this effect is mediated at least partly via inhibition of the PI3K/Akt
pathway.Hepatocellular carcinoma
(HCC) LY2940022 is currently
the fifth most common solid tumor worldwide and the fourth leading cause of
cancer-related death. To date, surgery is still the only curative treatment
but is only feasible in a small portion of patients
(1). Drug treatment is the
major therapy for patients with advanced stage disease. Unfortunately, the
response rate to traditional chemotherapy for HCC patients is unsatisfactory
(1). Novel pharmacological
therapy is urgently needed for patients with advanced HCC. In this regard, the
approval of sorafenib might open a new era of molecularly targeted therapy in
the treatment of HCC patients.Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a
type II transmembrane protein and a member of the TNF family, is a promising
anti-tumor agent under clinical investigation
(2). TRAIL functions by
engaging its receptors expressed on the surface of target cells. Five
receptors specific for TRAIL have been identified, including DR4/TRAIL-R1,
DR5/TRAIL-R2, DcR1, DcR2, and osteoprotegerin. Among TRAIL receptors, only DR4
and DR5 contain an effective death domain that is essential to formation of
death-inducing signaling complex (DISC), a critical step for TRAIL-induced
apoptosis. Notably, the trimerization of the death domains recruits an adaptor
molecule, Fas-associated protein with death domain (FADD), which subsequently
recruits and activates caspase-8. In type I cells, activation of caspase-8 is
sufficient to activate caspase-3 to induce apoptosis; however, in another type
of cells (type II), the intrinsic mitochondrial pathway is essential for
apoptosis characterized by cleavage of Bid and release of cytochrome
c from mitochondria, which subsequently activates caspase-9 and
caspase-3 (3).Although TRAIL induces apoptosis in malignant cells but sparing normal
cells, some tumor cells are resistant to TRAIL-induced apoptosis. Mechanisms
responsible for the resistance include receptors and intracellular resistance.
Although the cell surface expression of DR4 or DR5 is absolutely required for
TRAIL-induced apoptosis, tumor cells expressing these death receptors are not
always sensitive to TRAIL due to intracellular mechanisms. For example, the
cellular FLICE-inhibitory protein (c-FLIP), a homologue to caspase-8 but
without protease activity, has been linked to TRAIL resistance in several
studies (4,
5). In addition, inactivation
of Bax, a proapoptotic Bcl-2 family protein, resulted in resistance to TRAIL
in MMR-deficient tumors (6,
7), and reintroduction of Bax
into Bax-deficient cells restored TRAIL sensitivity
(8), indicating that the Bcl-2
family plays a critical role in intracellular mechanisms for resistance of
TRAIL.Bortezomib, a proteasome inhibitor approved clinically for multiple myeloma
and mantle cell lymphoma, has been investigated intensively for many types of
cancer (9). Accumulating
studies indicate that the combination of bortezomib and TRAIL overcomes the
resistance to TRAIL in various types of cancer, including acute myeloid
leukemia (4), lymphoma
(10–13),
prostate
(14–17),
colon (15,
18,
19), bladder
(14,
16), renal cell carcinoma
(20), thyroid
(21), ovary
(22), non-small cell lung
(23,
24), sarcoma
(25), and HCC
(26,
27). Molecular targets
responsible for the sensitizing effect of bortezomib on TRAIL-induced cell
death include DR4 (14,
27), DR5
(14,
20,
22–23,
28), c-FLIP
(4,
11,
21–23,
29), NF-κB
(12,
24,
30), p21
(16,
21,
25), and p27
(25). In addition, Bcl-2
family also plays a role in the combinational effect of bortezomib and TRAIL,
including Bcl-2 (10,
21), Bax
(13,
22), Bak
(27), Bcl-xL
(21), Bik
(18), and Bim
(15).Recently, we have reported that Akt signaling is a major molecular
determinant in bortezomib-induced apoptosis in HCC cells
(31). In this study, we
demonstrated that bortezomib overcame TRAIL resistance in HCC cells through
inhibition of the PI3K/Akt pathway. 相似文献
12.
Luyang Yu Wang Min Yun He Lingfeng Qin Haifeng Zhang Anton M. Bennett Hong Chen 《The Journal of biological chemistry》2009,284(20):13481-13488
Previously we have shown that tyrosine 718 of ASK1 when phosphorylated is
critical for SOCS1 binding and SOCS1-mediated degradation of ASK1. However,
the kinase and phosphatase responsible for phosphorylation and
dephosphorylation of ASK1 at Tyr-718 are unknown. In this study, we identified
JAK2 and SHP2 as a Tyr-718-specific kinase and phosphatase, respectively.
Interferon-γ (IFN-γ) induced degradation of ASK1 in normal but not
in SOCS1-KO endothelial cells (EC). IFN-γ-induced tyrosine
phosphorylation of ASK1 at Tyr-718 was blocked by a JAK2-specific inhibitor.
IFN-γ enhanced the association between JAK2 and ASK1, and the ASK1-JAK2
complex was labile and was stabilized by the proteasomal inhibitor MG132.
Furthermore, JAK2, but not JAK1, directly bound to and phosphorylated ASK1 at
Tyr-718, leading to an enhanced association of ASK1 with SOCS1 and subsequent
ASK1 degradation. Next, we showed that overexpression of the SH2-containing
protein-tyrosine phosphatase-2 (SHP2) augmented, whereas a
phosphatase-inactive mutant of SHP2 inhibited, TNF-induced ASK1
dephosphorylation. SHP2 associated with ASK1 in response to tumor necrosis
factor in EC. An SHP-2 substrate-trapping mutant formed a complex with
tyrosine-phosphorylated ASK1, suggesting that ASK1 is a direct SHP2 substrate.
Moreover, SHP2 wild type, but not a catalytically inactive mutant, dissociated
SOCS1 from ASK1. IFN-γ-induced ASK1 Tyr(P)-718 was enhanced in mouse EC
deficient in SHP2 (SHP2-KO). In contrast, tumor necrosis factor-induced
dephosphorylation of ASK1 at Tyr(P)-718 and activation of ASK1-JNK signaling,
as well as EC apoptosis, are significantly reduced in SHP2-KO EC. Our data
suggest that JAK2-SOCS1 and SHP2 reciprocally regulate ASK1 phosphorylation
and stability in response to cytokines.Myocardial infarction due to atherosclerosis of coronary arteries remains
the leading cause of death in the United States. It has become clear that
increases in inflammatory mediators represent a common pathogenic mechanism
for atherosclerosis (1). The
vascular cell that normally limits the inflammatory and atherosclerotic
process is the EC.3
Proinflammatory stimuli induce EC dysfunction, which is characterized by an
enhanced sensitivity of vascular cells to proinflammatory and proapoptotic
stimuli. Studies from our laboratory and others have demonstrated that ASK1
(apoptosis signal-regulating kinase-1), a member of MAP3K family
(2,
3), is an effector of
inflammation in EC
(4–8).
Almost all inflammatory stimuli such as tumor necrosis factor-α (TNF),
interleukin-1 (IL-1), and reactive oxygen species activate ASK1. Activated
ASK1 subsequently recruits and activates its downstream target MAP2Ks (MKK3/7
and MKK4/7), which in turn activate MAPKs (JNK and p38). Studies from
ASK1-deficient mice have also linked ASK1 to cardiovascular pathogenesis. ASK1
deletion in mice attenuated angiotensin II-induced cardiac hypertrophy and
remodeling. Neointimal formation due to proliferation of smooth muscle cells
in a cuff injury model is also attenuated by ASK1 deletion in mice
(9,
10).Although the linkage of ASK1 to inflammation is very strong, the mechanism
by which inflammatory stimuli, including TNF, activate ASK1 is not fully
understood. The identification of proteins associated with ASK1 and their
regulation on ASK1 have provided some insights into the mechanism for ASK1
activation. ASK1 is a 170-kDa protein that is composed of an inhibitory
N-terminal domain, an internal kinase domain, and a C-terminal regulatory
domain. One important regulatory mechanism of ASK1 activity is its Ser/Thr
phosphorylation and dephosphorylation by kinases and phosphatases. ASK1 is
basally phosphorylated at Ser-967 by an unidentified kinase, and 14-3-3 binds
to this site and inhibits ASK1 activity
(11,
12). TNF activates ASK1 in
part by dissociating these cellular inhibitors from ASK1
(4,
7). Recently, we have
identified PP2A as a phosphatase in TNF-induced dephosphorylation of ASK1
Ser(P)-967 (13). In addition
to the 14-3-3-binding site, Ser(P)-967, ASK1 is phosphorylated at Ser-83 by
Akt, leading to inhibition of ASK1 activity. In contrast, autophosphorylation
of ASK1 at Thr-838 leads to oligomerization and activation
(14). Phosphorylation of
Thr-845 can be negatively regulated by the phosphatase PP5
(15). Similarly, we found that
the ASK1 autophosphorylation at Thr-813 and Thr-842 also positively regulates
ASK1 signaling (16).In contrast to Ser/Thr phosphorylation, regulation of ASK1 by tyrosine
phosphorylation is less well understood. We have recently shown that ASK1 is
phosphorylated at Tyr-718, and this phosphorylation is critical for the
binding to suppressor of cytokine signaling-1 (SOCS1), a subunit of ubiquitin
ligase responsible for ASK1 degradation
(17). Tyrosine phosphorylation
of ASK1 is up-regulated in response to growth factors and cytokines such as
IFN-γ, whereas this phosphorylation can be down-regulated by TNF
treatment, resulting in ASK1 dissociation from SOCS1. However, the kinase and
phosphatase responsible for phosphorylation and dephosphorylation of ASK1 at
Tyr-718 are not known.The cytoplasmic tyrosine kinase, JAK2, autophosphorylates in response to
growth factors and cytokines, including IFN-γ. JAK2 then activates
cytokine receptors and other cytoplasmic proteins such as the STATs by
phosphorylating their key tyrosine residue. The JAK/STAT pathway can be
regulated by SH2-containing protein-tyrosine phosphatases such as SHP2
(18–20).
SHP2 is ubiquitously expressed and composed of two SH2 domains on the
N-terminal and C-terminal protein-tyrosine phosphatase (PTP) domain. The SH2
domain of SHP2 mediates the association with phosphotyrosine-containing
proteins present on activated receptors as well as on activated JAKs and
STATs; this association triggers activation of the tyrosine phosphatase domain
and subsequent dephosphorylation of substrates. SHP2 signals downstream of
receptor tyrosine kinases and cytokine receptors, and in most cases it serves
to positively transduce signals from these receptors. In other instances SHP2
has been shown to exhibit inhibitory signaling properties by negatively
regulating the JAK-STAT pathway
(19).In this study, we demonstrate that the IFN-γ-activated kinase JAK2
and TNF-activated SHP2 are the tyrosine kinase and phosphatase for Tyr-718 on
ASK1, respectively. The actions of both JAK2 and SHP2 affect protein turnover
of ASK1 and thus regulate ASK1/JNK-dependent proinflammatory and proapoptotic
pathways in EC. 相似文献
13.
14.
Yong Zhang Yong-Gang Wang Qi Zhang Xiu-Jie Liu Xuan Liu Li Jiao Wei Zhu Zhao-Huan Zhang Xiao-Lin Zhao Cheng He 《The Journal of biological chemistry》2009,284(18):12469-12479
TrkA receptor signaling is essential for nerve growth factor (NGF)-induced
survival and differentiation of sensory neurons. To identify possible
effectors or regulators of TrkA signaling, yeast two-hybrid screening was
performed using the intracellular domain of TrkA as bait. We identified
muc18-1-interacting protein 2 (Mint2) as a novel TrkA-binding protein and
found that the phosphotyrosine binding domain of Mint2 interacted with TrkA in
a phosphorylation- and ligand-independent fashion. Coimmunoprecipitation
assays showed that endogenous TrkA interacted with Mint2 in rat tissue
homogenates, and immunohistochemical evidence revealed that Mint2 and TrkA
colocalized in rat dorsal root ganglion neurons. Furthermore, Mint2
overexpression inhibited NGF-induced neurite outgrowth in both PC12 and
cultured dorsal root ganglion neurons, whereas inhibition of Mint2 expression
by RNA interference facilitated NGF-induced neurite outgrowth. Moreover, Mint2
was found to promote the retention of TrkA in the Golgi apparatus and inhibit
its surface sorting. Taken together, our data provide evidence that Mint2 is a
novel TrkA-regulating protein that affects NGF-induced neurite outgrowth,
possibly through a mechanism involving retention of TrkA in the Golgi
apparatus.The neurotrophin family member nerve growth factor
(NGF)3 is
essential for proper development, patterning, and maintenance of nervous
systems (1,
2). NGF has two known
receptors; TrkA, a single-pass transmembrane receptor-tyrosine kinase that
binds selectively to NGF, and p75, a transmembrane glycoprotein that binds all
members of the neurotrophin family
(3,
4). NGF binding activates the
kinase domain of TrkA, leading to autophosphorylation
(5). The resulting
phosphotyrosines become docking sites for adaptor proteins involved in signal
transduction pathways that lead to the activation of Ras, Rac,
phosphatidylinositol 3-kinase, phospholipase Cγ, and other effectors
(2,
6). Many of these
TrkA-interacting adaptor proteins have been identified and include, Grb2, APS,
SH2B, fibroblast growth factor receptor substrate 2 (FRS-2), Shc, and human
tumor imaginal disc 1 (TID1)
(7-10).
The identification of these binding partners has contributed greatly to our
understanding of the mechanisms underlying the functional diversity of
NGF-TrkA signaling.Studies have indicated that the transmission of NGF signaling in neurons
involves retrograde transport of NGF-TrkA complexes from the neurite tip to
the cell body
(11-14).
TrkA associates with components of cytoplasmic dynein, and it is thought that
vesicular trafficking of neurotrophins occurs via direct interaction of Trk
receptors with the dynein motor machinery
(14). Furthermore, the
atypical protein kinase C-interacting protein, p62, associates with TrkA and
plays a novel role in connecting receptor signals with the endosomal signaling
network required for mediating TrkA-induced differentiation
(15). Recently, the
membrane-trafficking protein Pincher has been found to mediate
macroendocytosis underlying retrograde signaling by TrkA
(16). Despite the progress
made to date in understanding Trk complex internalization and trafficking, the
mechanisms remain poorly understood.Mint2 (muc18-1-interacting protein 2) belongs to the Mint protein family,
which consists of three members, Mint1, Mint2, and Mint3. Mint proteins were
first identified as interacting proteins of the synaptic vesicle-docking
protein Munc18-1 (17,
18). Mint1 is also sometimes
referred to as mLIN-10, as it is the mammalian orthologue of the
Caenorhabditis elegans LIN-10
(19). Additionally, Mint1,
Mint2, and Mint3 are also referred to as X11α or X11, X11β or X11L
(X11-like), and X11γ or X11L2 (X11-like 2), respectively
(20). All Mint proteins
contain a conserved central phosphotyrosine binding (PTB) domain and two
contiguous C-terminal PDZ domains (repeated sequences in the brain-specific
protein PSD-95, the Drosophila septate junction protein Discs large,
and the epithelial tight junction protein ZO-1)
(17,
18,
21). Mint1 and Mint2 are
expressed only in neuronal tissue
(17), whereas Mint3 is
ubiquitously expressed (18).
Although the function of Mints proteins is not fully clear, their interactions
with the docking and exocytosis factors Mun18 -1 and CASK, ADP-ribosylation
factor (Arf) GTPases involved in vesicle budding
(22), and other synaptic
adaptor proteins, such as neurabin-II/spinophilin
(23), tamalin
(24), and kalirin-7
(25), all suggest possible
roles for Mints in synaptic vesicle docking and exocytosis. Mint proteins have
also been implicated in the trafficking and/or processing of β-amyloid
precursor protein (β-APP). Through their PTB domains, all three Mints
bind to a motif within the cytoplasmic domain of β-APP
(21,
26-29),
and Mint1 and Mint2 can stabilize β-APP, affect β-APP processing,
and inhibit the production and secretion of Aβ
(28,
30-32).
Although the mechanisms by which Mints inhibit β-APP processing are not
yet well known, Mints and their binding partners have emerged as potential
therapeutic targets for the treatment of Alzheimer disease.To uncover new TrkA-interacting factors and gain insight into the
mechanisms that guide TrkA intracellular trafficking and other aspects of TrkA
signaling, we conducted a yeast two-hybrid screen of a brain cDNA library
using the intracellular domain of TrkA as bait. The screen identified several
candidate TrkA-interacting proteins, one of which was Mint2. Follow-up binding
assays showed that the PTB domain of Mint2 alone was necessary and sufficient
for mediating the interaction with TrkA. Endogenous Mint2 was also
coimmunoprecipitated and colocalized with TrkA in rat DRG tissue.
Overexpression and knockdown studies showed that Mint2 could significantly
inhibit NGF-induced neurite outgrowth in both TrkA-expressing PC12 cells and
DRG neurons. Moreover, Mint2 was found to induce the retention of TrkA in the
Golgi apparatus and inhibit its surface sorting. Our results suggest that
Mint2 is a novel regulator of TrkA receptor signaling. 相似文献
15.
Sophie Pattingre Chantal Bauvy St��phane Carpentier Thierry Levade Beth Levine Patrice Codogno 《The Journal of biological chemistry》2009,284(5):2719-2728
Macroautophagy is a vacuolar lysosomal catabolic pathway that is stimulated
during periods of nutrient starvation to preserve cell integrity. Ceramide is
a bioactive sphingolipid associated with a large range of cell processes. Here
we show that short-chain ceramides (C2-ceramide and
C6-ceramide) and stimulation of the de novo ceramide
synthesis by tamoxifen induce the dissociation of the complex formed between
the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. This
dissociation is required for macroautophagy to be induced either in response
to ceramide or to starvation. Three potential phosphorylation sites,
Thr69, Ser70, and Ser87, located in the
non-structural N-terminal loop of Bcl-2, play major roles in the dissociation
of Bcl-2 from Beclin 1. We further show that activation of c-Jun N-terminal
protein kinase 1 by ceramide is required both to phosphorylate Bcl-2 and to
stimulate macroautophagy. These findings reveal a new aspect of sphingolipid
signaling in up-regulating a major cell process involved in cell adaptation to
stress.Macroautophagy (referred to below as “autophagy”) is a
vacuolar, lysosomal degradation pathway for cytoplasmic constituents that is
conserved in eukaryotic cells
(1–3).
Autophagy is initiated by the formation of a multimembrane-bound autophagosome
that engulfs cytoplasmic proteins and organelles. The last stage in the
process results in fusion with the lysosomal compartments, where the
autophagic cargo undergoes degradation. Basal autophagy is important in
controlling the quality of the cytoplasm by removing damaged organelles and
protein aggregates. Inhibition of basal autophagy in the brain is deleterious,
and leads to neurodegeneration in mouse models
(4,
5). Stimulation of autophagy
during periods of nutrient starvation is a physiological response present at
birth and has been shown to provide energy in various tissues of newborn pups
(6). In cultured cells,
starvation-induced autophagy is an autonomous cell survival mechanism, which
provides nutrients to maintain a metabolic rate and level of ATP compatible
with cell survival (7). In
addition, starvation-induced autophagy blocks the induction of apoptosis
(8). In other contexts, such as
drug treatment and a hypoxic environment, autophagy has also been shown to be
cytoprotective in cancer cells
(9,
10). However, autophagy is
also part of cell death pathways in certain situations
(11). Autophagy can be a
player in apoptosis-independent type-2 cell death (type-1 cell death is
apoptosis), also known as autophagic cell death. This situation has been shown
to occur when the apoptotic machinery is crippled in mammalian cells
(12,
13). Autophagy can also be
part of the apoptotic program, for instance in tumor necrosis
factor-α-induced cell death when NF-κB is inhibited
(14), or in human
immunodeficiency virus envelope-mediated cell death in bystander naive CD4 T
cells (15). Moreover autophagy
has recently been shown to be required for the externalization of
phosphatidylserine, the eat-me signal for phagocytic cells, at the surface of
apoptotic cells (16).The complex relationship between autophagy and apoptosis reflects the
intertwined regulation of these processes
(17,
18). Many signaling pathways
involved in the regulation of autophagy also regulate apoptosis. This
intertwining has recently been shown to occur at the level of the molecular
machinery of autophagy. In fact the anti-apoptotic protein Bcl-2 has been
shown to inhibit starvation-induced autophagy by interacting with the
autophagy protein Beclin 1
(19). Beclin 1 is one of the
Atg proteins conserved from yeast to humans (it is the mammalian orthologue of
yeast Atg6) and is involved in autophagosome formation
(20). Beclin 1 is a platform
protein that interacts with several different partners, including hVps34
(class III phosphatidylinositol 3-kinase), which is responsible for the
synthesis of phosphatidylinositol 3-phosphate. The production of this lipid is
important for events associated with the nucleation of the isolation membrane
before it elongates and closes to form autophagosomes in response to other Atg
proteins, including the Atg12 and
LC32
(microtubule-associated protein light chain 3 is the mammalian orthologue of
the yeast Atg8) ubiquitin-like conjugation systems
(3,
21). Various partners
associated with the Beclin 1 complex modulate the activity of hVps34. For
instance, Bcl-2 inhibits the activity of this enzyme, whereas UVRAG, Ambra-1,
and Bif-1 all up-regulate it
(22,
23).In view of the intertwining between autophagy and apoptosis, it is
noteworthy that Beclin 1 belongs to the BH3-only family of proteins
(24–26).
However, and unlike most of the proteins in this family, Beclin 1 is not able
to trigger apoptosis when its expression is forced in cells
(27). A BH3-mimetic drug,
ABT-737, is able to dissociate the Beclin 1-Bcl-2 complex, and to trigger
autophagy by mirroring the effect of starvation
(25).The sphingolipids constitute a family of bioactive lipids
(28–32)
of which several members, such as ceramide and sphingosine 1-phosphate, are
signaling molecules. These molecules constitute a “sphingolipid
rheostat” that determines the fate of the cell, because in many settings
ceramide is pro-apoptotic and sphingosine 1-phosphate mitigates this apoptotic
effect (31,
32). However, ceramide is also
engaged in a wide variety of other cell processes, such as the formation of
exosomes (33),
differentiation, cell proliferation, and senescence
(34). Recently we showed that
both ceramide and sphingosine 1-phosphate are able to stimulate autophagy
(35,
36). It has also been shown
that ceramide triggers autophagy in a large panel of mammalian cells
(37–39).
However, elucidation of the mechanism by which ceramide stimulates autophagy
is still in its infancy. We have previously demonstrated that ceramide induces
autophagy in breast and colon cancer cells by inhibiting the Class I
phosphatidylinositol 3-phosphate/mTOR signaling pathway, which plays a central
role in inhibiting autophagy
(36). Inhibition of mTOR is
another hallmark of starvation-induced autophagy
(17). This finding led us to
investigate the effect of ceramide on the Beclin 1-Bcl-2 complex. The results
presented here show that ceramide is more potent than starvation in
dissociating the Beclin 1-Bcl-2 complex (see Ref.
40). This dissociation is
dependent on three phosphorylation sites (Thr69, Ser70,
and Ser87) located in a non-structural loop of Bcl-2. Ceramide
induces the c-Jun N-terminal kinase 1-dependent phosphorylation of Bcl-2.
Expression of a dominant negative form of JNK1 blocks Bcl-2 phosphorylation,
and thus the induction of autophagy by ceramide. These findings help to
explain how autophagy is regulated by a major lipid second messenger. 相似文献
16.
17.
Formin-homology (FH) 2 domains from formin proteins associate processively
with the barbed ends of actin filaments through many rounds of actin subunit
addition before dissociating completely. Interaction of the actin
monomer-binding protein profilin with the FH1 domain speeds processive barbed
end elongation by FH2 domains. In this study, we examined the energetic
requirements for fast processive elongation. In contrast to previous
proposals, direct microscopic observations of single molecules of the formin
Bni1p from Saccharomyces cerevisiae labeled with quantum dots showed
that profilin is not required for formin-mediated processive elongation of
growing barbed ends. ATP-actin subunits polymerized by Bni1p and profilin
release the γ-phosphate of ATP on average >2.5 min after becoming
incorporated into filaments. Therefore, the release of γ-phosphate from
actin does not drive processive elongation. We compared experimentally
observed rates of processive elongation by a number of different FH2 domains
to kinetic computer simulations and found that actin subunit addition alone
likely provides the energy for fast processive elongation of filaments
mediated by FH1FH2-formin and profilin. We also studied the role of FH2
structure in processive elongation. We found that the flexible linker joining
the two halves of the FH2 dimer has a strong influence on dissociation of
formins from barbed ends but only a weak effect on elongation rates. Because
formins are most vulnerable to dissociation during translocation along the
growing barbed end, we propose that the flexible linker influences the
lifetime of this translocative state.Formins are multidomain proteins that assemble unbranched actin filament
structures for diverse processes in eukaryotic cells (reviewed in Ref.
1). Formins stimulate
nucleation of actin filaments and, in the presence of the actin
monomer-binding protein profilin, speed elongation of the barbed ends of
filaments
(2-6).
The ability of formins to influence elongation depends on the ability of
single formin molecules to remain bound to a growing barbed end through
multiple rounds of actin subunit addition
(7,
8). To stay associated during
subunit addition, a formin molecule must translocate processively on the
barbed end as each actin subunit is added
(1,
9-12).
This processive elongation of a barbed end by a formin is terminated when the
formin dissociates stochastically from the growing end during translocation
(4,
10).The formin-homology
(FH)2 1 and
2 domains are the best conserved domains of formin proteins
(2,
13,
14). The FH2 domain is the
signature domain of formins, and in many cases, is sufficient for both
nucleation and processive elongation of barbed ends
(2-4,
7,
15). Head-to-tail homodimers
of FH2 domains (12,
16) encircle the barbed ends
of actin filaments (9). In
vitro, association of barbed ends with FH2 domains slows elongation by
limiting addition of free actin monomers. This “gating” behavior
is usually explained by a rapid equilibrium of the FH2-associated end between
an open state competent for actin monomer association and a closed state that
blocks monomer binding (4,
9,
17).Proline-rich FH1 domains located N-terminal to FH2 domains are required for
profilin to stimulate formin-mediated elongation. Individual tracks of
polyproline in FH1 domains bind 1:1 complexes of profilin-actin and transfer
the actin directly to the FH2-associated barbed end to increase processive
elongation rates
(4-6,
8,
10,
17).Rates of elongation and dissociation from growing barbed ends differ widely
for FH1FH2 fragments from different formin homologs
(4). We understand few aspects
of FH1FH2 domains that influence gating, elongation or dissociation. In this
study, we examined the source of energy for formin-mediated processive
elongation, and the influence of FH2 structure on elongation and dissociation
from growing ends. In contrast to previous proposals
(6,
18), we found that fast
processive elongation mediated by FH1FH2-formins is not driven by energy from
the release of the γ-phosphate from ATP-actin filaments. Instead, the
data show that the binding of an actin subunit to the barbed end provides the
energy for processive elongation. We found that in similar polymerizing
conditions, different natural FH2 domains dissociate from growing barbed ends
at substantially different rates. We further observed that the length of the
flexible linker between the subunits of a FH2 dimer influences dissociation
much more than elongation. 相似文献
18.
Lilly Y. W. Bourguignon Weiliang Xia Gabriel Wong 《The Journal of biological chemistry》2009,284(5):2657-2671
19.
20.
Il-Ha Lee Craig R. Campbell Sung-Hee Song Margot L. Day Sharad Kumar David I. Cook Anuwat Dinudom 《The Journal of biological chemistry》2009,284(19):12663-12669
It has recently been shown that the epithelial Na+ channel
(ENaC) is compartmentalized in caveolin-rich lipid rafts and that
pharmacological depletion of membrane cholesterol, which disrupts lipid raft
formation, decreases the activity of ENaC. Here we show, for the first time,
that a signature protein of caveolae, caveolin-1 (Cav-1), down-regulates the
activity and membrane surface expression of ENaC. Physical interaction between
ENaC and Cav-1 was also confirmed in a coimmunoprecipitation assay. We found
that the effect of Cav-1 on ENaC requires the activity of Nedd4-2, a ubiquitin
protein ligase of the Nedd4 family, which is known to induce ubiquitination
and internalization of ENaC. The effect of Cav-1 on ENaC requires the
proline-rich motifs at the C termini of the β- and γ-subunits of
ENaC, the binding motifs that mediate interaction with Nedd4-2. Taken
together, our data suggest that Cav-1 inhibits the activity of ENaC by
decreasing expression of ENaC at the cell membrane via a mechanism that
involves the promotion of Nedd4-2-dependent internalization of the
channel.Amiloride-sensitive epithelial Na+ channels
(ENaC)3 are membrane
proteins that are expressed in salt-absorptive epithelia, including the distal
collecting tubules of the kidney, the mucosa of the distal colon, the
respiratory epithelium, and the excretory ducts of sweat and salivary glands
(1–4).
Na+ absorption via ENaC is critical to the normal regulation of
Na+ and fluid homeostasis and is important for maintaining blood
pressure (5) and the volume of
fluid in the respiratory passages
(6). Increased ENaC activity
has been implicated in the salt-sensitive inherited form of hypertension,
Liddle''s syndrome (7), and
dehydration of the surface of the airway epithelium in the pathology
associated with cystic fibrosis lung disease
(8).Expression of ENaC at the cell membrane surface is regulated by the E3
ubiquitin protein ligase, Nedd4-2 (neural precursor cell
expressed developmentally down-regulated
protein 4) (9). Interaction
between the WW domains of Nedd4-2 and the proline-rich PY motifs
(PPPXY) on ENaC is essential for Nedd4-2 to exert a negative effect
on the channel (10,
11). This interaction leads to
ubiquitination-dependent internalization of ENaC
(12,
13). Several regulators of
ENaC exert their effects on the channel by modulating the action of Nedd4-2.
For instance, serum and glucocorticoid-dependent protein kinase
(14), protein kinase B
(15), and G protein-coupled
receptor kinase (16)
up-regulate activity of ENaC by inhibiting Nedd4-2. Although the details of
cellular mechanisms that underlie internalization of ENaC remain to be
elucidated, the physiological significance of Nedd4-dependent internalization
of the channel has been well established. For instance, heritable mutations
that delete the cytosolic termini of the β-or γ-subunit of ENaC,
which contain the proline-rich motifs, are known to cause hyperactivity of
ENaC in the kidney (17) and
increase cell surface expression of the channel
(7,
18).The plasma membranes of most cell types contain lipid raft microdomains
that are enriched with glycosphingolipid and cholesterol
(19), that have distinctive
biophysical properties, and that selectively include or exclude signaling
molecules (20). These
microdomains promote clustering of an array of integral membrane proteins in
the membrane leaflets (21) and
may be important for organizing cascades of signaling molecules
(22,
23). Processes in which raft
microdomains are involved include the intracellular transport of proteins and
lipids to the cell membrane
(24), the endocytotic
retrieval of membrane proteins
(25,
26), and signal transduction
(27,
28). In addition, segregation
of signaling molecules within lipid rafts may facilitate cross-talk between
signal transduction pathways
(29), a phenomenon that may be
important in ensuring rapid and efficient integration of multiple cellular
signaling events (30,
31). Of particular interest is
the subpopulation of lipid rafts enriched with caveolin proteins. Caveolin-1
(Cav-1), a major caveolin isoform expressed in nonmuscle cells, has been
identified as being involved in diverse cellular functions, such as vesicular
transport, cholesterol homeostasis, and signal transduction
(32). Cav-1 also regulates the
activity and membrane expression of ion channels and transporters
(28).In epithelia, the majority of lipid rafts exist at the apical membrane
surface (22). Pools of ENaC
(33–36)
and several proteins that regulate activity of ENaC, such as Nedd4
(37), protein kinase B
(38), protein kinase C
(39), Go
(40), and the G
protein-coupled receptor kinase
(41), have been identified in
detergent-insoluble and cholesterol-rich membrane fractions from a variety of
cell types, consistent with localization of these proteins in lipid rafts.
Furthermore, detergent-free buoyant density separation of lipid rafts has
revealed the presence of Cav-1 with ENaC in the lipid raft-rich membrane
fraction (35). The
physiological role of lipid rafts in the regulation of ENaC has been the
subject of many recent investigations. Most of these studies used a
pharmacological agent, methyl-β-cyclodextrin (MβCD), to promote
redistribution of proteins away from the cholesterol-enriched membrane
domains. The results were, however, inconclusive. In some studies, MβCD
treatment was found to inhibit open probability
(42) or cell surface
expression of ENaC (35),
whereas others found no direct effect of MβCD on the channel
(33,
43).Despite a number of studies into the role of lipid rafts on the regulation
of ENaC, little is known about the physiological relevance of caveolins to the
function of this ion channel. In the present study, we use gene interference
and gene expression techniques to determine the role of Cav-1 in the
regulation of ENaC activity. We provide evidence of the association of Cav-1
with ENaC and evidence that Cav-1 negatively regulates both activity and
abundance of ENaC at the surface of epithelial cells. Importantly, we
demonstrate, for the first time, that the mechanism by which Cav-1 regulates
activity of ENaC involves the E3 ubiquitin protein ligase, Nedd4-2. 相似文献